AIM ImmunoTech Inc. financial data

Symbol
AIM on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
2117 Sw Highway 484, Ocala, FL
State of incorporation
DE
Fiscal year end
December 31
Former names
HEMISPHERX BIOPHARMA INC (to 8/26/2019)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 117 % -89.6%
Debt-to-equity 169 %
Return On Equity -398 % -504%
Return On Assets -148 % -148%
Operating Margin -14.7K % -21.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.7M shares +30.4%
Common Stock, Shares, Outstanding 58.7M shares +20.2%
Entity Public Float 31.8M USD -12.2%
Common Stock, Value, Issued 59K USD +22.9%
Weighted Average Number of Shares Outstanding, Basic 57.7M shares +18.6%
Weighted Average Number of Shares Outstanding, Diluted 57.7M shares +18.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 190K USD -2.06%
Revenue from Contract with Customer, Excluding Assessed Tax 190K USD -2.06%
Research and Development Expense 7.73M USD -21.5%
General and Administrative Expense 20.3M USD +46%
Costs and Expenses 28.1M USD +18.8%
Operating Income (Loss) -27.9M USD -19%
Net Income (Loss) Attributable to Parent -23.9M USD -15.2%
Earnings Per Share, Basic -0.47 USD/shares -9.3%
Earnings Per Share, Diluted -0.47 USD/shares +62.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 915K USD -94%
Marketable Securities, Current 6.29M USD -12.3%
Accounts Receivable, after Allowance for Credit Loss, Current 1.18M USD -29.4%
Assets, Current 7.57M USD -66.7%
Property, Plant and Equipment, Net 117K USD -14%
Operating Lease, Right-of-Use Asset 653K USD -10.2%
Other Assets, Noncurrent 2.72M USD +29.2%
Assets 13.6M USD -51.2%
Accounts Payable, Current 6.26M USD +125%
Employee-related Liabilities, Current 1K USD -96.6%
Accrued Liabilities, Current 1.01M USD -41.3%
Liabilities, Current 10.1M USD +114%
Operating Lease, Liability, Noncurrent 437K USD -19.5%
Liabilities 10.7M USD
Retained Earnings (Accumulated Deficit) -421M USD -6.03%
Stockholders' Equity Attributable to Parent 2.91M USD -87.1%
Liabilities and Equity 13.6M USD -51.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.82M USD -30.8%
Net Cash Provided by (Used in) Financing Activities 2.83M USD +2729%
Net Cash Provided by (Used in) Investing Activities -158K USD -103%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 58.7M shares +20.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.14M USD +41.4%
Deferred Tax Assets, Valuation Allowance 36.8M USD +19.4%
Deferred Tax Assets, Gross 38.4M USD +20.2%
Operating Lease, Liability 669K USD -10.8%
Depreciation 9K USD -18.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -23.9M USD -15.2%
Property, Plant and Equipment, Gross 1.47M USD -5.72%
Operating Lease, Liability, Current 232K USD +12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 244K USD +10.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 276K USD +4.55%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 88K USD -37.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 159K USD -20.5%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +27.7%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 133K USD -33.5%
Additional Paid in Capital 424M USD +1.17%
Amortization of Intangible Assets 49K USD +36.1%
Interest Expense 202K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%